# Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant

> **NCT00228176** · PHASE3 · TERMINATED · sponsor: **Sanofi** · enrollment: 661 (actual)

## Conditions studied

- Carotid Artery Plaque
- Arteriosclerosis
- Obesity
- Metabolic Syndrome X

## Interventions

- **DRUG:** Rimonabant
- **DRUG:** Placebo (for Rimonabant)

## Key facts

- **NCT ID:** NCT00228176
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-08
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 661 (ACTUAL)
- **Why stopped:** Company decision taken in light of demands by certain national health authorities
- **Last updated:** 2016-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00228176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00228176, "Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00228176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*